Abstract
INTRODUCTION AND AIMS: Among recipients of kidney transplants, non-adherence with prescribed immunosuppressive medications commonly occurs [Denhaerynck K, et al., 2005]. Several factors are associated with post-transplant medication non-adherence [Prendergast M.B., Gaston R.S., 2010]. Possible barriers to adherence include patients’ personal schedules and routines, characteristics of the medicines and their dosage and schedules [Gordon E.J, et al, 2009] Aim of study - to assess the advantages of once daily tacrolimus intake for recipients of kidney allograft METHODS: For study, we had two comparative groups of patients. Once daily regimen of tacrolimus intake was switched at 46 patients (main group). Control group of 32 patients had twice daily regimen. Exclusion criteria was increased level of serum creatinine, anemia, hypertension. Examination of patients included laboratory tests of blood and urine, tacrolimus level, ultrasound of transplant. All patients completed Kidney Disease Quality of life Short Form 36 (KDQOL SF-36) questionnairy and immunosuppressive therapy adherence scale. The study was performed after 6 months after the switch. Statistical analysis was performed by Statistica 6.0. SP814 Figure CONCLUSIONS: Conversion to once daily intake of tacrolimus in renal transplant recipients is significantly safe and effective, increases quality of life and therapy adherence. Non-adherence can be significant predictor of early graft dysfunction.